Sustained or markedly elevated blood pressure - report for dose adjustment.
Before you read
Test yourself first: 3 questions
Question 1 of 3
A client with depression is started on venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI). Which assessment is most important for the nurse to monitor?
Answer: A. Venlafaxine can cause dose-related increases in blood pressure due to its noradrenergic activity, so monitoring blood pressure is important. While GI effects occur, hypertension is the key SNRI-specific safety concern. Routine clotting times and visual acuity are not primary monitoring needs.
Question 2 of 3
A client is started on venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI). Which baseline and ongoing assessment is most important due to a known adverse effect of this drug?
Answer: A. Venlafaxine and other SNRIs can cause dose-dependent increases in blood pressure due to norepinephrine activity. Blood pressure should be monitored at baseline and during therapy, especially at higher doses. This is a distinguishing adverse effect of SNRIs compared with SSRIs.
Question 3 of 3
A client taking venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), should be monitored for which adverse effect related to its norepinephrine activity?
Answer: B. Venlafaxine, an SNRI, can cause a dose-related increase in blood pressure due to its norepinephrine reuptake inhibition. Blood pressure should be monitored, particularly at higher doses, in addition to the usual serotonergic side effects.
Keep the streak going with more questions like these, each with a full rationale.
What is venlafaxine?
At higher doses its norepinephrine effect can raise blood pressure. It has a short half-life, so missed doses or abrupt stopping cause a notably uncomfortable discontinuation syndrome.
Key points to remember
- Dose-dependent hypertension is a hallmark concern; norepinephrine effect increases at higher doses.
- Carries the same black box suicide warning as other antidepressants in patients under 25.
- Short half-life makes discontinuation syndrome (dizziness, electric-shock sensations, nausea) common with missed/stopped doses.
- Can cause serotonin syndrome when combined with MAOIs or other serotonergic drugs.
- Common effects: nausea, dry mouth, sweating, insomnia, and sexual dysfunction.
- Therapeutic mood effect takes 2-4 weeks.
Signs & symptoms
- Nausea, dry mouth, sweating, insomnia
- Dose-related ↑ BP → monitor
Nursing priorities
- Monitor blood pressure at baseline and regularly, especially with dose increases.
- Assess for suicidal ideation, particularly early in therapy.
- Teach strict adherence and never to skip doses given the short half-life.
- Taper slowly when discontinuing to prevent discontinuation syndrome.
- Watch for serotonin syndrome with concurrent serotonergic agents.
Patient teaching
- Take with food at the same time each day; do not skip doses.
- Expect 2-4 weeks for full effect; do not stop abruptly.
- Report headaches, palpitations, or signs of high blood pressure.
- Avoid alcohol and other serotonergic medications.
Red flags: report now
- Sustained or markedly elevated blood pressure - report for dose adjustment.
- Serotonin syndrome (hyperthermia, rigidity, agitation, clonus) - hold and report.
- New/worsening suicidal ideation.
- Never combine with or give within 14 days of an MAOI.
References
Clinical references for this topic
